Interestingly this was despite SMARCA4-altered NSCLC patients having significantly increased TMB (a predictive biomarker for CIT response33) relative to the SMARCA4 WT population (Supplementary Fig. 1a). The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.